The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Management of cognitive deficits in Major Depressive Disorder (MDD) remains an important unmet need. This meta-analysis evaluated the effects of vortioxetine on cognition in patients with MDD. METHODS: Random effects meta-analysis was applied to three randomized, double-blind, placebo-controlled 8-week trials of vortioxetine (5-20mg/day) in MDD, and separately to two duloxetine-referenced trials. The primary outcome measure was change in Digit Symbol Substitution Test (DSST) score. Standardized effect sizes (SES) versus placebo (Cohen's d ) were used as input. Path analysis was employed to determine the extent to which changes in DSST were mediated independently of a change in Montgomery-Åsberg Depression Rating Scale (MADRS) score. Meta-analysis was applied to MADRS-adjusted and -unadjusted SES values. Changes on additional cognitive tests were evaluated (source studies only). RESULTS: Before adjustment for MADRS, vortioxetine separated from placebo on DSST score (SES 0.25-0.48; nominal p < 0.05) in all individual trials, and statistically improved DSST performance versus placebo in meta-analyses of the three trials (SES = 0.35; p < 0.0001) and two duloxetine-referenced trials (SES = 0.26; p = 0.001). After adjustment for MADRS, vortioxetine maintained DSST improvement in one individual trial ( p = 0.001) and separation from placebo was maintained in meta-analyses of all three trials (SES = 0.24; p < 0.0001) and both duloxetine-referenced trials (SES 0.19; p = 0.01). Change in DSST with duloxetine failed to separate from placebo in individual trials and both meta-analyses. Change in DSST statistically favored vortioxetine versus duloxetine after MADRS adjustment (SES = 0.16; p = 0.04). CONCLUSIONS: Vortioxetine, but not duloxetine, significantly improved cognition, independent of depressive symptoms. Vortioxetine represents an important treatment for MDD-related cognitive dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In clinical studies of patients with MDD, vortioxetine has shown significant and clinically relevant effects not only on depressive symptoms, but also on the physical and cognitive symptoms of depression (Christensen et al., 2018a;Kelliny et al., 2015;McIntyre et al., 2016).”
From Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment (2021) · cites this paper as McIntyre et al., 2016
Experimental — accuracy not yet measuredIn the citing paper
“Hitherto, only 2 antidepressants (ie, duloxetine and vortioxetine) have demonstrated direct, independent, and clinically relevant effects on cognitive dysfunction in MDD. 8”
From Cognitive Impairment in Major Depressive Disorder (2019) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“The I2 value in the meta-analysis of unadjusted data for the three trials was 42% (data not shown), indicating a low likelihood that study heterogeneity had a relevant impact on effect estimates (Higgins et al., 2003).”
MethodA new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 2×
“These were similarly designed, 8-week, randomized, double-blind, placebo-controlled trials in patients who met the Diagnostic and Statistical Manual of Mental Disorders criteria for recurrent MDD (Fourth Edition, Text Revision; DSM-IV-TR; American Psychiatric Association, 2000b) and had a MADRS (Montgomery and Åsberg,…”
BackgroundMethodCognitive impairment in depression: a systematic review and meta-analysis
Rock, P. L., Roiser, J. P., Riedel, W. J., & Blackwell, A. D. (2014) · Psychological Medicine · doi:10.1017/s0033291713002535 · Cited by 2,161 · cited 1×
“7 (Lee et al., 2012; Snyder, 2013; Rock et al., 2014), a magnitude of cognitive decline that is anticipated to have a profound impact on occupational and school performance.”
BackgroundSnyder, H. R. (2013) · Psychological Bulletin · doi:10.1037/a0028727 · Cited by 1,667 · cited 2×
“…tests) observed in patients with MDD relative to healthy controls, for which metaanalyses indicate that the typical SES are 0.2–0.7 (Lee et al., 2012; Snyder, 2013; Rock et al., 2014), a magnitude of cognitive decline that is anticipated to have a profound impact on occupational and school…”
BackgroundInfluentialDistributed Disturbances in Brain Structure and Function in Schizophrenia
(2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.1 · Cited by 969
McIntyre, R. S., Cha, D. S., Soczynska, J. K., Woldeyohannes, H. O., Gallaugher, L. A., Kudlow, P., Alsuwaidan, M., & Baskaran, A. (2013) · Depression and Anxiety · doi:10.1002/da.22063 · Cited by 765
Self-citationA meta-analysis of cognitive deficits in first-episode Major Depressive Disorder
Lee, R. S. C., Hermens, D. F., Porter, M. A., & Redoblado-Hodge, M. A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.10.023 · Cited by 737 · cited 1×
“7 (Lee et al., 2012; Snyder, 2013; Rock et al., 2014), a magnitude of cognitive decline that is anticipated to have a profound impact on occupational and school performance.”
Background
Research works printed but not linked: 1
- Ditlevsen S Christensen U Lynch J Damsgaard MT Keiding N (2005b). The mediation proportion: a structural equation approach for estimating the proportion of exposure effect on outcome explained by an intermediate variable. Appendix A, The mediation proportion: details of the basic statistical regression model. Epidemiology 16: 114– 120. 15613954 · DOI · Paper page
Cited by
Malhi, G. S., Bell, E., Bassett, D., Boyce, P., Bryant, R., Hazell, P., Hopwood, M., Lyndon, B., Mulder, R., Porter, R., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420979353 · Cited by 614
“There are data suggesting that vortioxetine may be helpful for some aspects of cognitive function in major depression, but the effects are relatively narrow and are related to the treatment of acute depression (McIntyre et al., 2016).”
BackgroundCognitive Impairment in Major Depressive Disorder
Pan, Z., Park, C., Brietzke, E., Zuckerman, H., Rong, C., Mansur, R. B., Fus, D., Subramaniapillai, M., Lee, Y., & McIntyre, R. S. (2019) · CNS Spectrums · doi:10.1017/s1092852918001207 · Cited by 320
“Duloxetine did not exhibit a statistically significant improvement when compared to placebo on composite measures of cognitive function in contradistinction to vortioxetine.(67) In addition, vortioxetine appears to improve a broader range of cognitive functions (ie, executive function, learning, memory, processing spe…”
MethodResultSelf-citationPrévot, T., & Sibille, E. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0727-3 · Cited by 231
Miskowiak, K., Burdick, K., Martinez‐Aran, A., Bonnin, C., Bowie, C., Carvalho, A., Gallagher, P., Lafer, B., López‐Jaramillo, C., Sumiyoshi, T., et al. (2017) · Bipolar Disorders · doi:10.1111/bdi.12534 · Cited by 216
Self-citationMiskowiak, K., Burdick, K., Martinez‐Aran, A., Bonnin, C., Bowie, C., Carvalho, A., Gallagher, P., Lafer, B., López‐Jaramillo, C., Sumiyoshi, T., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12595 · Cited by 213
Self-citationAdult Hippocampal Neurogenesis in Major Depressive Disorder and Alzheimer’s Disease
Berger, T., Lee, H., Young, A. H., Aarsland, D., & Thuret, S. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.03.010 · Cited by 207
HIV, Depression, and Cognitive Impairment in the Era of Effective Antiretroviral Therapy
Rubin, L. H., & Maki, P. M. (2019) · Current HIV/AIDS Reports · doi:10.1007/s11904-019-00421-0 · Cited by 178
Mansur, R. B., Ahmed, J., Cha, D. S., Woldeyohannes, H. O., Subramaniapillai, M., Lovshin, J., Lee, J. G., Lee, J.-H., Brietzke, E., Reininghaus, E. Z., et al. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.09.056 · Cited by 164
Self-citationBaune, B. T., Brignone, M., & Larsen, K. G. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx070 · Cited by 140
“In addition, a recent meta-analysis by McIntyre et al. included 3 randomized controlled trials (RCTs) and showed that vortioxetine significantly improved cognition measured by the Digit Symbol Substitution Test (DSST), independent of changes in overall depressive symptoms (McIntyre et al., 2016).”
BackgroundMethodResultInfluentialThe efficacy of vortioxetine on anhedonia in patients with major depressive disorder
Cao, B., Park, C., Subramaniapillai, M., Lee, Y., Iacobucci, M., Mansur, R. B., Zuckerman, H., Phan, L., & McIntyre, R. S. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00017 · Cited by 139
“, loss of consciousness for >1 h), other neurological disorders, or unstable systemic medical diseases that, in the opinion of the investigator, are likely to affect the central nervous system, (13) pregnant and/or breastfeeding, (14) received investigational agents as part of a separate study within 30 days of the sc…”
BackgroundMethodSelf-citationFagiolini, A., Florea, I., Loft, H., & Christensen, M. C. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.106 · Cited by 127
Self-citationAdvances in antidepressants for treating post-stroke depression
Paolucci, S. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1334765 · Cited by 110
Gill, H., Gill, B., Rodrigues, N. B., Lipsitz, O., Rosenblat, J. D., El-Halabi, S., Nasri, F., Mansur, R. B., Lee, Y., & McIntyre, R. S. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.11.020 · Cited by 93
Self-citationVortioxetine: A Review in Cognitive Dysfunction in Depression
Frampton, J. E. (2016) · Drugs · doi:10.1007/s40265-016-0655-3 · Cited by 90
“24 after, adjusting for the change in MADRS total score [24].”
MethodLu, Y., Ho, C. S., McIntyre, R. S., Wang, W., & Ho, R. C. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.06.007 · Cited by 90
“Vortioxetine is a novel multimodal antidepressant that has demonstrated significant improvement in cognitive function when compared to other antidepressants (McIntyre et al., 2016), although the neurobiological mechanisms underlying the precognitive effects of this agent are not fully understood.”
Self-citationTorrisi, S. A., Geraci, F., Tropea, M. R., Grasso, M., Caruso, G., Fidilio, A., Musso, N., Sanfilippo, G., Tascedda, F., Palmeri, A., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00693 · Cited by 86
McIntyre, R. S., Loft, H., & Christensen, M. C. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s296451 · Cited by 84
Self-citationAgüera-Ortíz, L., García-Ramos, R., Pérez, F. J. G., López‐Álvarez, J., Rodríguez, J. M. M., Rodríguez, F. J. O., Pueyo, J. O., Valero, C. P., & Porta-Etessam, J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.638651 · Cited by 95
“A meta-analysis of 3 controlled trials concluded that vortioxetine, aside from its efficacy in depression, significantly improves cognitive function compared with duloxetine (97).”
BackgroundmGlu2/3 Receptor Antagonists as Novel Antidepressants
Chaki, S. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.03.008 · Cited by 73
Miskowiak, K. W., Seeberg, I., Jensen, M. B., Balanzá‐Martínez, V., Bonnín, C. D. M., Bowie, C. R., Carvalho, A. F., Dols, A., Douglas, K. M., Gallagher, P., et al. (2022) · Bipolar Disorders · doi:10.1111/bdi.13193 · Cited by 84
Self-citationVortioxetine for cognitive enhancement in major depression: From animal models to clinical research
Bennabi, D., Haffen, E., & Van Waes, V. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00771 · Cited by 75
Baune, B. T., Sluth, L. B., & Olsen, C. K. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.12.056 · Cited by 73
Self-citationSalagre, E., Solé, B., Tomioka, Y., Fernandes, B. S., Hidalgo-Mazzei, D., Garriga, M., Jimenez, E., Sanchez-Moreno, J., Vieta, E., & Grande, I. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.06.034 · Cited by 71
Sumiyoshi, T., Watanabe, K., Noto, S., Sakamoto, S., Moriguchi, Y., Tan, K. H. X., Hammer-Helmich, L., & Fernandez, J. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.064 · Cited by 70
Advances in Management of Neuropsychiatric Syndromes in Neurodegenerative Diseases
Cummings, J., Ritter, A., & Rothenberg, K. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1058-4 · Cited by 68
De Diego-Adeliño, J., Crespo, J. M., Mora, F., Neyra, A., Iborra, P., Gutiérrez-Rojas, L., & Salonia, S. F. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2019705 · Cited by 67
“independent of antidepressant effects [53,54].”
Cognitive dysfunctions in depression – significance, description and treatment prospects
Czerwińska, A., & Pawłowski, T. (2020) · Psychiatria Polska · doi:10.12740/pp/onlinefirst/105415 · Cited by 85
“Comparing vortioxetine with duloxetine also showed statistically significant difference in DSST results in favor of vortioxetine [63].”
Fourrier, C., Sampson, E., Mills, N. T., & Baune, B. T. (2018) · Trials · doi:10.1186/s13063-018-2829-7 · Cited by 65
“Furthermore, vortioxetine is the only antidepressant listed in the RANZCP guidelines that is likely to be useful in enhancing the remittance of cognitive symptoms of depression [39], since it has been demonstrated to have beneficial effects on the cognitive symptoms seen in MDD [40].”
BackgroundColwell, M., Tagomori, H., Chapman, S., Gillespie, A. L., Cowen, P. J., Harmer, C. J., & Murphy, S. E. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02249-6 · Cited by 74
Liu, Y., Chen, Y., Liang, X., Li, D., Zheng, Y., Zhang, H., Cui, Y., Chen, J., Liu, J., & Qiu, S. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00272 · Cited by 65
Chokka, P., Bougie, J., Proulx, J., Tvistholm, A. H., & Ettrup, A. (2019) · CNS Spectrums · doi:10.1017/s1092852919000786 · Cited by 56
Wang, G., Si, T., Li, L., Fang, Y., Wang, C., Wang, L., Tan, K. H. X., Ettrup, A., Eriksen, H. F., Luo, S., et al. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s195505 · Cited by 55
“The task involves attention, processing speed, and executive functioning, and has shown sensitivity-to -change in MDD populations.(22) DSST score is calculated as the total number of correct symbols within a 90-s period (possible score range 0–133), with higher scores reflecting better performance.”
MethodSubramaniapillai, M., Mansur, R. B., Zuckerman, H., Park, C., Lee, Y., Iacobucci, M., Cao, B., Ho, R., Lin, K., Phan, L., et al. (2019) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2019.07.006 · Cited by 49
Self-citationCaruso, G., Grasso, M., Fidilio, A., Torrisi, S. A., Musso, N., Geraci, F., Tropea, M. R., Privitera, A., Tascedda, F., Puzzo, D., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.809541 · Cited by 49
“At clinical level, VTX has proven more effective than SSRIs in the treatment of specific clinical domains, such as cognitive deficits in elderly depressed patients (McIntyre et al., 2016; Thase et al., 2016), underlining its therapeutic potential for the treatment of cognitive impairment in depression (Bennabi et al.”
BackgroundVortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial
McIntyre, R. S., Phan, L., Kwan, A. T. H., Mansur, R. B., Rosenblat, J. D., Guo, Z., Le, G. H., Lui, L. M. W., Teopiz, K. M., Ceban, F., et al. (2023) · Brain · doi:10.1093/brain/awad377 · Cited by 50
Self-citationMillan, M. J., Rivet, J.-M., & Gobert, A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116672342 · Cited by 45
“In line with these observations, there are encouraging findings with vortioxetine and cognitive performance both in preclinical models and in patients, notably elderly subjects (Katona et al., 2012; McIntyre et al., 2016).”
BackgroundResultInoue, T., Sasai, K., Kitagawa, T., Nishimura, A., & Inada, I. (2020) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12956 · Cited by 45
Efficacy of vortioxetine on the physical symptoms of major depressive disorder
Christensen, M. C., Florea, I., Lindstén, A., & Baldwin, D. S. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118788826 · Cited by 47
“(Harrison et al., 2016; McIntyre et al., 2016) as well as functional capacity (Christensen et al., 2018; Mahableshwarkar et al., 2015).”
BackgroundMethodInfluentialHuang, I.-C., Chang, T.-S., Chen, C., & Sung, J.-Y. (2022) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac054 · Cited by 41
“…u lt ip le c ou n tr ie s: A u st ra li a, C an ad a, F in la n d , F ra n ce , G er m an y, L at vi a, M ex ic o, S er bi a, S lo va ki a, S ou th A fr ic a, U kr ai n e, a n d t h e U n it ed S ta te s. its efficacy on self-rated cognitive deficits and employment position (McIntyre et al., 2017).”
Mattingly, G. W., Ren, H., Christensen, M. C., Katzman, M. A., Polosan, M., Simonsen, K., & Hammer-Helmich, L. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.824831 · Cited by 47
Vortioxetina: una nueva alternativa en el trastorno depresivo mayor
Salagre, E., Grande, I., Solé, B., Sánchez‐Moreno, J., & Vieta, E. (2017) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2017.06.006 · Cited by 45
Umbricht, D., Niggli, M., Sanwald-Ducray, P., Deptula, D., Moore, R., Grünbauer, W., Boak, L., & Fontoura, P. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.18m12470 · Cited by 39
Jutten, R. J., Harrison, J., de Jong, F. J., Aleman, A., Ritchie, C. W., Scheltens, P., & Sikkes, S. A. M. (2017) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.01.004 · Cited by 40
“This measure has performed as being sensitive to changes in recently reported clinical drug trials of cognitively enhancing compounds [39].”
MethodSelf-citationMultimodal antidepressant vortioxetine causes analgesia in a mouse model of chronic neuropathic pain
Zuena, A. R., Maftei, D., Alemà, G., Moro, F. D., Lattanzi, R., Casolini, P., & Nicoletti, F. (2018) · Molecular Pain · doi:10.1177/1744806918808987 · Cited by 40
Findling, R. L., DelBello, M. P., Zuddas, A., Emslie, G. J., Ettrup, A., Petersen, M. L., Schmidt, S. N., & Rosén, M. (2022) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2022.01.004 · Cited by 50
Christensen, M. C., Schmidt, S. N., & Grande, I. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.06.024 · Cited by 39
Keefe, R. S. E., Cañadas, E., Farlow, D., & Etkin, A. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.21020125 · Cited by 37
Levada, O. A., & Troyan, A. S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.03.040 · Cited by 37
McIntyre, R. S., Rosenblat, J. D., Rodrigues, N. B., Lipsitz, O., Chen-Li, D., Lee, J. G., Nasri, F., Subramaniapillai, M., Kratiuk, K., Wang, A., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113993 · Cited by 33
Self-citationNierenberg, A. A., Loft, H., & Olsen, C. K. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.02.006 · Cited by 31
Self-citationBiederman, J., Lindstén, A., Sluth, L. B., Petersen, M. L., Ettrup, A., Eriksen, H. F., & Fava, M. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119832538 · Cited by 33
Vortioxetine as a new frontier in the treatment of chronic neuropathic pain: a review and update
Adamo, D., Calabria, E., Coppola, N., Pecoraro, G., & Mignogna, M. D. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211034320 · Cited by 39
Vortioxetine: A new alternative for the treatment of major depressive disorder
Salagre, E., Grande, I., Solé, B., Sánchez‐Moreno, J., & Vieta, E. (2018) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2018.02.005 · Cited by 31
Pehrson, A. L., Pedersen, C. S., Tølbøl, K. S., & Sánchez, C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00162 · Cited by 31
“A recent metaanalysis of three randomized placebo controlled clinical trials in MDD patients demonstrated that vortioxetine induced significant improvements compared to placebo in the digitsymbol substitution test, a putative measure of processing speed and executive function, independently of its effects on mood (McI…”
MethodVortioxetine – pharmacological properties and use in mood disorders. The current state of knowledge
Krupa, A. J., Wojtasik-Bakalarz, K., & Siwek, M. (2022) · Psychiatria Polska · doi:10.12740/pp/onlinefirst/151570 · Cited by 31
When the drugs don’t work: treatment-resistant schizophrenia, serotonin and serendipity
Lowe, P., Krivoy, A., Porffy, L., Henriksdottir, E., Whiskey, E., & Shergill, S. S. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317737003 · Cited by 30
Nicola, M. D., Pepe, M., Montanari, S., Spera, M. C., Panaccione, I., Simonetti, A., & Sani, G. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.02.006 · Cited by 27
Sun, X., Weiwei, Y., Wang, M., Hu, J., & Li, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1135085 · Cited by 27
Zhang, X., Cai, Y., Hu, X., Lu, C. Y., Nie, X., & Shi, L. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.922648 · Cited by 33
“Vortioxetine was statistically more efficacious on cognitive function than escitalopram, nortriptyline, SSRIs and TCAs (38) and their impact independent of depressive symptoms (47), and the superiority compared”
BackgroundHaro, J. M., Hammer-Helmich, L., Saragoussi, D., Ettrup, A., & Larsen, K. G. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s206825 · Cited by 30
“Both pharmacological and nonpharmacological antidepressant treatments may improve cognitive symptoms to some extent when improving mood symptoms; however, to date, only vortioxetine has been shown to have robust and direct effects on cognitive function.(48,49) In a recent interventional, open-label, real-world Canadia…”
BackgroundZhou, Y., Wang, C., Lan, X., Zheng, W., Li, H., Chao, Z., Wu, K., McIntyre, R. S., & Ning, Y. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.10.037 · Cited by 25
Self-citationNgen, C. C., Zain, A. M., Hemrungrojn, S., Ung, E. K., Kwansanit, P., Yong, K. C. A., Chong, M. S. W., Inpa, C., Yen, T. H., Yeoh, B. B. D., et al. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1477746 · Cited by 25
Pytka, K., Gawlik, K., Pawlica-Gosiewska, D., Witalis, J., & Waszkielewicz, A. M. (2016) · Metabolic Brain Disease · doi:10.1007/s11011-016-9932-9 · Cited by 23
“However, recent meta-analysis of clinical trials showed that only vortioxetine significantly improved cognition in depressed patients (McIntyre et al. 2016).”
ResultMcIntyre, R. S. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s150589 · Cited by 25
“of vortioxetine involve a combination of monoaminergic and glutamatergic effects.(23) Vortioxetine has also been shown to”
Self-citationInkster, B., Zai, G. C., Lewis, G., & Miskowiak, K. W. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0270-z · Cited by 27
Wang, G., Xiao, L., Ren, H., Simonsen, K., Ma, J., Xu, X., Guo, P., Wang, Z., Bai, L., Heldbo Reines, E., et al. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s358253 · Cited by 22
Cognitive impairment in people remitted from major depression
Porter, R., & Douglas, K. M. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30278-0 · Cited by 22
An update on potential pharmacotherapies for cognitive impairment in bipolar disorder
Johnson, D. E., McIntyre, R. S., Mansur, R. B., & Rosenblat, J. D. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2194488 · Cited by 25
“functioning in adults with recurrent MDD independent of its effects on depressive mood [80].”
BackgroundSelf-citationNicola, M. D., Pepe, M., Panaccione, I., Moccia, L., Dattoli, L., Molinaro, M., Sani, G., Janiri, L., & McIntyre, R. S. (2020) · CNS Spectrums · doi:10.1017/s109285292000173x · Cited by 22
“DSST is used to explore cognitive skills involving attention, processing speed, spatial perception, visual scanning, and executive function, which has shown sensitivity to change in MDD subjects.(41) The DSST score was calculated by the clinician as the number of correct symbols at baseline, 3months, and 6months.”
MethodSelf-citationPilc, A., Machaczka, A., Kawalec, P., Smith, J. L., & Witkin, J. M. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2111415 · Cited by 21
Haniff, Z. R., Bocharova, M., Mantingh, T., Rucker, J., Velayudhan, L., Taylor, D. M., Young, A. H., Aarsland, D., Vernon, A. C., & Thuret, S. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108641 · Cited by 22
“Vortioxetine (an SSRI) may improve executive dysfunction in MDD but the data are inconsistent (McIntyre, Harrison, Loft, Jacobson, & Olsen, 2016; Pehrson, Li, Sanchez, & Gulinello, 2021).”
Chokka, P. R., Tvistholm, A. H., Bougie, J. K., Clerzius, G., & Ettrup, A. (2020) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000001805 · Cited by 21
“Antidepressant treatments may improve cognitive symptoms to some extent when improving mood symptoms; to date, however, only vortioxetine has been shown to have robust and direct effects on cognition.(33,35,37) Results of the primary analysis of the AtWoRC study showed highly significant positive correlations between…”
BackgroundLewis, V., Rodrigue, B., Arsenault, E., Zhang, M., Taghavi‐Abkuh, F., Silva, W. C. C., Myers, M., Matta‐Camacho, E., & Aguilar‐Valles, A. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15652 · Cited by 21
“…showed cognitive improvement in psychomotor performance, verbal memory and delayed free recall, or learning and memory (Constant et al., 2005; Schrijvers et al., 2009; Soczynska et al., 2014), with vortioxetine, an SSRI, showing the most robust pro- cognitive effects in MDD (McIntyre et al., 2016).”
Boyce, P. M., & Ma, C. (2021) · Australian Prescriber · doi:10.18773/austprescr.2020.064 · Cited by 26
Hemispheric stroke: Mood disorders
Harciarek, M., & Mańkowska, A. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-822290-4.00007-4 · Cited by 27
What do we know about pseudodementia?
Mouta, S., Vaz, I. F., Pires, M., Ramos, S., & Figueiredo, D. (2023) · General Psychiatry · doi:10.1136/gpsych-2022-100939 · Cited by 18
Wang, G., Tan, K. H. X., Ren, H., & Hammer-Helmich, L. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s230403 · Cited by 18
Yang, Y. K., Chen, C., Tsai, C.-F., Chang, C., Lai, T.-J., Lee, C.-T., Lin, C., Lan, T., & Herr, K. J. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1980869 · Cited by 19
Functional brain abnormalities in major depressive disorder using the Hilbert-Huang transform
Yu, H., Li, F., Wu, T., Li, R., Yao, L., Wang, C., & Wu, X. (2018) · Brain Imaging and Behavior · doi:10.1007/s11682-017-9816-6 · Cited by 17
“Major depressive disorder (MDD) is a commonly occurring mental disease characterized by persistent depressed mood, cognitive impairments, anhedonia, and thinking retardation (Zeng et al. 2012; Otte et al. 2016; McIntyre et al. 2016).”
BackgroundZhang, J., & Zhang, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1215977 · Cited by 19
“DSST relied on the integrity of executive function, processing speed, attention, spatial perception, and visual scanning (24).”
MethodClinical pharmacological innovation in the treatment of depression
Witkin, J. M., Golani, L. K., & Smith, J. L. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2198703 · Cited by 17
“Lack of full patient response and remission Increased efficacy [6] Weeks of treatment typically required More rapid onset [7–9] Not always a large overall beneficial effect Increased level of improvement [10] After treatment response, some symptoms often remain Full symptom cluster relief [11,12] Tolerability and side…”
BackgroundInvolvement of muscarinic receptor mechanisms in antidepressant drug action
Witkin, J. M., Smith, J. L., Golani, L. K., Brooks, E. A., & Martin, A. E. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.03.003 · Cited by 18
McCue, M., Sarkey, S., Eramo, A., François, C., & Parikh, S. V. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03608-1 · Cited by 15
Functional cognitive disorders: identification and management
Poole, N. A., Cope, S. R., Bailey, C., & Isaacs, J. D. (2019) · BJPsych Advances · doi:10.1192/bja.2019.38 · Cited by 15
Papalexi, E., Galanopoulos, A., Kontis, D., Markopoulou, M., Balta, G., Karavelas, E., Panagiotidis, P., Vlachos, T., & Ettrup, A. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04109-5 · Cited by 16
Cumbo, E., Adair, M., Åström, D. O., & Christensen, M. C. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1037816 · Cited by 17
“Vortioxetine has been shown to have dose-dependent efficacy in patients with MDD, with the greatest therapeutic effects achieved at the maximum dosage of 20 mg/day (Baldwin et al., 2016a; McIntyre et al., 2016; Thase et al., 2016; Florea et al., 2017; Christensen et al., 2018, 2021; Iovieno et al., 2021; McIntyre et a…”
BackgroundSerotonin 5-HT3 receptor antagonism potentiates the antidepressant activity of citalopram
Perez-Palomar, B., Mollinedo-Gajate, I., Berrocoso, E., Meana, J. J., & Ortega, J. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.02.020 · Cited by 14
Żelaszczyk, D., Jakubczyk, M., Pytka, K., Rapacz, A., Walczak, M., Janiszewska, P., Pańczyk, K., Żmudzki, P., Słoczyńska, K., Marona, H., et al. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126679 · Cited by 14
Yang, K., Stepanov, V., Amini, N., Martinsson, S., Takano, A., Bundgaard, C., Bang‐Andersen, B., Sánchez, C., Halldin, C., Farde, L., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0442-4 · Cited by 14
Depression interacts with allostatic load to predict cognitive decline in middle age
Perlman, G., Cogo‐Moreira, H., Wu, C., Herrmann, N., & Swardfager, W. (2022) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2022.105922 · Cited by 14
G-protein coupled receptors and synaptic plasticity in sleep deprivation
Parmar, S., Tadavarty, R., & Sastry, B. R. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i11.954 · Cited by 11
Filippis, S. D., Pugliese, A., Christensen, M. C., Rosso, G., Nicola, M. D., Simonsen, K., & Ren, H. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s375294 · Cited by 13
Cuomo, A., Aguglia, A., Berardis, D. D., Ventriglio, A., Gesi, C., & Fagiolini, A. M. (2024) · Annals of General Psychiatry · doi:10.1186/s12991-024-00505-1 · Cited by 13
Does gender influence cognitive function in non-psychotic depression?
Caldirola, D., Sangiorgio, E., Riva, A., Grassi, M., Alciati, A., Scialò, C., & Perna, G. (2017) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2017.10.002 · Cited by 13
Slowed Processing Speed Disrupts Patient Expectancy in Late Life Depression
Rutherford, B. R., Choi, C. J., Choi, J.-W., Mass, B., He, X., O'Boyle, K., Sneed, J. R., Brown, P. J., Brickman, A. M., Wall, M. M., et al. (2020) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2020.11.001 · Cited by 13
He, H., Wang, W., Lyu, J., Zheng, J., Guo, L., An, X., Fan, Y., & Ma, X. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.10.018 · Cited by 13
“…is not known despite several meta-analyses having been reported (Baldwin et al., 2016, Berhan and Barker, 2014, Fu and Chen, 2015, Li et al., 2016, Li et al., 2016, McIntyre et al., 2016, Meeker et al., 2015, Naik et al., 2016, Pae et al., M AN US CR IP T AC CE PT ED 6 2015, Thase et al., 2016).”
ResultVortioxetine Improves Context Discrimination in Mice Through a Neurogenesis Independent Mechanism
Felice, D., Guilloux, J., Pehrson, A. L., Li, Y., Mendez‐David, I., Gardier, A. M., Sánchez, C., & David, D. J. P. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00204 · Cited by 12
“Recent clinical and preclinical data suggest that treatment with VORT has beneficial effect on aspects of cognitive function (Al-Sukhni et al., 2015; Mahableshwarkar et al., 2015; Sanchez et al., 2015; McIntyre et al., 2016).”
BackgroundThe Challenge of Antidepressant Therapeutics in Alzheimer’s Disease
Lozupone, M., Montagna, M. L., D’Urso, F., Piccininni, C., Rinaldi, A., Beghi, M., Cornaggia, C., Sardone, R., Solfrizzi, V., Daniele, A., et al. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-42667-5_10 · Cited by 10
Cognitive symptoms domain in major depressive disorder-revisited
Naguy, A., Moodliar‐Rensburg, S., & Alamiri, B. (2020) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2020.102216 · Cited by 11
Kim, H. K., Baik, S. Y., Kim, Y. W., & Lee, S. (2021) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12220 · Cited by 10
Metadata
- Authors
- McIntyre, R., Harrison, J., Loft, H., Jacobson, W., & Olsen, C.
- Corresponding author
- McIntyre, RS
- ORCID
- Harrison, J
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-06-15
- Volume
- 19
- Issue
- 10
- Pages
- pyw055
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC5091829
- OpenAlex
- W2436735416
- Cited by
- 185
- References
- 44
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 17 · 2023: 14 · 2022: 25 · 2021: 23 · 2020: 20 · 2019: 27 · 2018: 17 · 2017: 15 · 2016: 5
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- HighWire Press Open Archive (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Takeda Pharmaceuticals U.S.A.
- H. Lundbeck A/S
- University of California, San Diego
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- vortioxetine, major depressive disorder, cognitive function, cognitive impairment, duloxetine, Digit Symbol Substitution Test, neuropsychological outcomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.